Astrana Health earnings release, August 6, 2026

Astrana Health, Inc. (ASTH) · Form 8-K, Item 2.02 · Filed · SEC filing

Astrana Health, Inc. Reports Second Quarter

2026 Results

Company to Host Conference Call on Thursday,

August 6, 2026, at 2:30 p.m. PT/5:30 p.m. ET

ALHAMBRA, Calif.,

August 6, 2026

/PRNewswire/

-- Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”)

(NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the second quarter ended June 30, 2026.

“Our second quarter results reflect the strength of Astrana’s physician-centric, AI-native healthcare operating system and the disciplined execution of our team,” said Brandon Sim, President and Chief Executive Officer of Astrana Health. “We continue to see accelerating demand from both providers and payers for our platform, driving strong growth, record-high adjusted diluted EPS, and robust free cash flow generation. Our performance gives us the confidence to raise our adjusted EBITDA guidance for 2026 even as we reinvest a substantial portion of our first-half outperformance into attractive growth opportunities that we believe will further strengthen our earnings power over time.”

Financial Highlights for Second Quarter Ended June 30, 2026:

All comparisons are to the three months ended

June 30, 2025 unless otherwise stated.

Financial Highlights for Six Months Ended June 30, 2026:

All comparisons are to the six months ended

June 30, 2025 unless otherwise stated.

Recent Operating Highlights

Segment Results for three months ended June 30,

2026:

All comparisons are to the three months ended

June 30, 2025 unless otherwise stated.

* Percentage change of over 500%.

2026 Guidance:

Based on the Company’s existing business, current view of existing market conditions, and assumptions, Astrana is providing the following guidance for total revenue and Adjusted

EBITDA for the three months ending September 30, 2026, updating Adjusted EBITDA guidance for the year ending December 31, 2026, and reaffirming revenue and free cash flow guidance for the year ending December 31, 2026.

Financial statements

Income Statement

Three Months Ended June 30, 2026 — All comparisons are to the three months ended June 30, 2025 unless otherwise stated. (in thousands)

Three Months Ended June 30, 2026 – Care PartnersThree Months Ended June 30, 2026 – Care DeliveryThree Months Ended June 30, 2026 – Care EnablementThree Months Ended June 30, 2026 – Intersegment EliminationThree Months Ended June 30, 2026Three Months Ended June 30, 2026 – Corporate CostsThree Months Ended June 30, 2026 – Consolidated Total
Total revenues932,83674,69685,598-120,610)$—972,520
% change vs. prior year quarter48.0%95.0%109.0%
Cost of services805,46961,92351,665-50,559)868,498
General and administrative expenses72,13314,55216,158-70,091)21,39854,150
Depreciation and amortization12,3621,1881,37862215,550
Total expenses889,96477,66369,201-120,650)22,020938,198
Income (loss) from operations42,872-2,96716,39740-1-22,02034,322
% change vs. prior year quarter-14.0%-238.0%

Income Statement

Three Months Ending September 30, 2026 (in millions)

Three Months Ending September 30, 2026 – Guidance Range – LowThree Months Ending September 30, 2026 – Guidance Range – HighYear Ending December 31, 2026 – Guidance Range – LowYear Ending December 31, 2026 – Guidance Range – High
Total revenue1,0001,0303,8004,100
Adjusted EBITDA72.577.5255280
Free cash flow105132.5

Income Statement

Three Months Ended June 30, — (UNAUDITED) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
RevenueCapitation and other revenue, net972,520654,8081,937,6201,275,196
Operating expensesCost of services, excluding depreciation and amortization868,498576,8391,727,8551,125,900
Operating expensesGeneral and administrative expenses54,15050,725115,88894,623
Operating expensesDepreciation and amortization15,5506,90431,02813,752
Operating expensesTotal expenses938,198634,4681,874,7711,234,275
Operating expensesIncome from operations34,32220,34062,84940,921
Other (expense) incomeIncome (loss) from equity method investments5483812,268-486
Other (expense) incomeInterest expense-15,997-7,382-32,098-14,690
Other (expense) incomeInterest income5,9072,3369,7234,647
Other (expense) incomeUnrealized gain (loss) on investments4,732145,816-30
Other (expense) incomeOther (loss) income-2,3021,136-1,640-3,934
Other (expense) incomeTotal other expense, net-7,112-3,515-15,931-14,493
Other (expense) incomeIncome before provision for income taxes27,21016,82546,91826,428
Other (expense) incomeProvision for income taxes8,7586,60915,3359,991
Other (expense) incomeNet income18,45210,21631,58316,437
Other (expense) incomeNet (loss) income attributable to non-controlling interests-1,287793-2,592322
Other (expense) incomeNet income attributable to Astrana Health, Inc.19,7399,42334,17516,115
Other (expense) incomeEarnings per share – basic0.40.190.70.33
Other (expense) incomeEarnings per share – diluted0.40.190.690.33
Other (expense) incomeWeighted average shares of common stock outstanding – basic49,115,83549,187,88548,986,95348,831,265
Other (expense) incomeWeighted average shares of common stock outstanding – diluted49,778,02849,470,67749,418,27849,162,653

Income Statement

Three Months Ended June 30, (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30,Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30,Six Months Ended June 30, – 2025
Net income18,45210,21631,58316,437
Interest expense15,9977,38232,09814,690
Interest income-5,907)-2,336)-9,723)-4,647)
Provision for income taxes8,7586,60915,3359,991
Depreciation and amortization15,5506,90431,02813,752
EBITDA52,85028,775100,32150,223
(Income) loss from equity method investments-548)-381)-2,268)486
Other, net4,800-17,998-215,450-314,257-4
Stock-based compensation11,78711,70921,68219,519
Adjusted EBITDA68,88948,101135,18584,485
Total revenue972,520654,8081,937,6201,275,196
Adjusted EBITDA margin7%7%7%7%

Income Statement

Three Months Ended June 30, (in thousands, except for share and per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30,Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30,Six Months Ended June 30, – 2025
Net income18,45210,21631,58316,437
(Income) loss from equity method investments-548)-381)-2,268)486
Other, net (1)4,8007,99815,45014,257
Stock-based compensation11,78711,70921,68219,519
Amortization of intangible assets attributable to acquisitions13,8066,17927,65612,442
Tax adjustments-5,965-2-4,637-3-13,490-2-9,238
Adjusted net income attributable to non-controlling interests-2,561-4-3,715-5-4,489-4-6,032
Adjusted net income attributable to Astrana Health, Inc.39,77127,36976,12447,871
Weighted average shares of common stock outstanding – diluted49,778,02849,470,67749,418,27849,162,653

Income Statement

Year Ending December 31, 2026 — Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA (in thousands)

Year Ending December 31, 2026 – Guidance Range – LowYear Ending December 31, 2026 – Guidance Range – High
Net income59,00074,000
Interest expense49,00053,000
Provision for income taxes38,00044,000
Depreciation and amortization65,00065,000
EBITDA211,000236,000
Income from equity method investments-4,000-4,000
Other, net9,0009,000
Stock-based compensation39,00039,000
Adjusted EBITDA255,000280,000

Balance Sheet

June 30, 2026 — (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

June 30, 2026 – (Unaudited)December 31, 2025
Current assetsCash and cash equivalents400,792429,474
Current assetsReceivables, net (including amounts from related parties)465,080374,465
Current assetsIncome taxes receivable1,799
Current assetsOther receivables24,11326,385
Current assetsPrepaid expenses and other current assets25,85726,264
Current assetsLoans receivable3,3184,926
Current assetsTotal current assets919,160863,313
Non-current assetsProperty and equipment, net62,56757,332
Non-current assetsIntangible assets, net243,312270,968
Non-current assetsGoodwill886,995865,305
Non-current assetsIncome taxes receivable, net of current portion26,22026,220
Non-current assetsLoans receivable, net of current portion49,27348,724
Non-current assetsInvestments in other entities – equity method27,80525,637
Non-current assetsOperating lease right-of-use assets39,19435,738
Non-current assetsOther assets27,55425,424
Non-current assetsTotal non-current assets1,362,9201,355,348
Non-current assetsTotal assets (1)2,282,0802,218,661
Current liabilitiesAccounts payable and accrued expenses245,860195,912
Current liabilitiesFiduciary accounts payable3,7713,524
Current liabilitiesIncome taxes payable2,082
Current liabilitiesMedical liabilities415,765335,705
Current liabilitiesOperating lease liabilities8,9387,809
Current liabilitiesCurrent portion of long-term debt53,84847,865
Current liabilitiesOther liabilities17,37524,458
Current liabilitiesTotal current liabilities747,639615,273
Non-current liabilitiesDeferred tax liability8,7955,491
Non-current liabilitiesOperating lease liabilities, net of current portion33,97531,552
Non-current liabilitiesLong-term debt, net of current portion and deferred financing costs882,650990,904
Non-current liabilitiesOther long-term liabilities10,44217,107
Non-current liabilitiesTotal non-current liabilities935,8621,045,054
Non-current liabilitiesTotal liabilities (1)1,683,5011,660,327
Mezzanine deficitNon-controlling interest in Allied Physicians of California, a Professional Medical Corporation (“APC”)-242,261-234,962
Stockholders’ equityCommon stock, $0.001 par value per share; 100,000,000 shares authorized, 49,226,943 and 48,885,358 shares issued and outstanding, excluding 10,695,758 and 10,571,011 treasury shares, as of June 30, 2026 and December 31, 2025, respectively4949
Stockholders’ equityAdditional paid-in capital487,820470,863
Stockholders’ equityRetained earnings342,355308,379
Stockholders’ equityTotal stockholders’ equity830,224779,291
Stockholders’ equityNon-controlling interests10,61614,005
Stockholders’ equityTotal equity840,840793,296
Stockholders’ equityTotal liabilities, mezzanine deficit, and stockholders’ equity2,282,0802,218,661

Cash Flow

Six Months Ended June 30, — (UNAUDITED) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30,Six Months Ended June 30, – 2025
Cash flows from operating activitiesNet income31,58316,437
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization31,02813,752
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of debt issuance cost2,2801,740
Adjustments to reconcile net income to net cash provided by operating activities:Share-based compensation21,68219,519
Adjustments to reconcile net income to net cash provided by operating activities:Non-cash lease expense4,1312,559
Adjustments to reconcile net income to net cash provided by operating activities:Deferred tax2,734-1,961
Adjustments to reconcile net income to net cash provided by operating activities:Change in fair value of contingent consideration liabilities-4,820)3,351
Adjustments to reconcile net income to net cash provided by operating activities:Other-6,735)560
Adjustments to reconcile net income to net cash provided by operating activities:Changes in operating assets and liabilities, net of business combinations18,92151,571
Adjustments to reconcile net income to net cash provided by operating activities:Net cash provided by operating activities100,804107,528
Cash flows from investing activitiesPayments for business and assets acquisition, net of cash acquired-3,739)
Cash flows from investing activitiesPurchases of property and equipment-7,878)-4,490
Cash flows from investing activitiesOther2,5451,019
Cash flows from investing activitiesNet cash used in investing activities-9,072)-3,471
Cash flows from financing activitiesDividends paid-199)-6,233
Cash flows from financing activitiesBorrowings on debt412,000
Cash flows from financing activitiesRepayment of debt-103,933)-431,357
Cash flows from financing activitiesDeferred financing cost-17,241

Cash Flow

Six Months Ended June 30, — Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net cash provided by operating activities100,804107,528
Purchases of property and equipment-7,878-4,490
Free cash flow92,926103,038

Cash Flow

Year Ending December 31, 2026 — Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (in thousands)

Year Ending December 31, 2026 – Guidance Range – LowYear Ending December 31, 2026 – Guidance Range – High
Net cash provided by operating activities125,000145,000
Cash used in purchases of property and equipment-20,000-12,500
Free cash flow105,000132,500
Full release

See “Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA,” “Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow,” and “Use of Non-GAAP Financial Measures” below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward-Looking Statements” below for additional information.

Conference Call and Webcast Information:

Astrana will host a conference call at 2:30 p.m. PT/5:30 p.m. ET today (Thursday, August 6,

2026), during which management will discuss the results of the second quarter ended

June 30, 2026. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:

The conference call can also be accessed via webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=w7Ip0KQB

An accompanying slide presentation will be available in PDF format on the “IR Calendar” page of the Company’s website ( https://ir.astranahealth.com/news-events/ir-calendar) after issuance of the earnings release and will be furnished as an exhibit to Astrana’s current report on Form 8-K to be filed with the SEC, accessible at www.sec.gov.

Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.

Note About Consolidated Entities

The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities (“VIEs”) in which the Company is the primary beneficiary. Non-controlling interests represent third party equity ownership interests in the Company’s consolidated entities (including certain VIEs). The amount of net income or loss attributable to non-controlling interests is disclosed in the Company’s consolidated statements of income.

About Astrana Health, Inc.

Astrana Health is a physician-centric, AI-powered healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across the healthcare system.

Today, Astrana supports more than 20,000 providers and approximately 1.5 million patients in value-based care arrangements through its affiliated provider networks, management services organization, and integrated care delivery clinics spanning primary, specialty, and ancillary care. Together,

Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for all. For more information, visit www.astranahealth.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company’s guidance for the quarter ending September 30, 2026 and the year ending December 31, 2026, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving... (truncated)ll as long-term value, ability to respond to the changing environment, statements about the Company's liquidity, and successful completion and implementation of strategic growth plans, acquisition strategy, and merger integration efforts, as well as statements regarding the material weakness in internal control over financial reporting and the Company’s ability to remediate such material weakness in a timely manner. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company’s management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the SEC, including, without limitation the risk factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31,

2025, and subsequent quarterly reports on Form 10-Q. Any forward-looking statement made by the Company in this release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations investors@astranahealth.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.